Generate Biomedicines co-founder and CTO Gevorg Grigoryan says Nvidia Corp (NASDAQ: NVDA) contributes more than capital to the startup’s artificial intelligence drug discovery efforts. The chipmaker provides critical technical expertise in accelerated computing.

Grigoryan told Benzinga via email that Nvidia holds a unique vantage point on computing evolution. This includes deep expertise in GPU architecture and highly optimized software. These elements extract maximum performance from hardware for demanding biological workloads.

Technical Exchange Over Funding

The relationship has evolved into a technical exchange rather than simple financial backing. Nvidia helps Generate tackle challenges in running computationally intensive models. These models generate, evaluate, and refine potential medicines efficiently.

Grigoryan noted that this expertise allows Generate to run complex biological workloads at greater scale. The collaboration focuses on making these processes as efficient as possible.

Strategic Value in Scaling

Generate’s platform uses AI throughout drug development. This ranges from designing new molecules to informing clinical planning. Extracting value requires more than powerful hardware access.

Nvidia’s experience in performance optimization becomes strategically valuable as Generate scales its AI platform. This reflects a broader industry trend where infrastructure providers contribute engineering expertise alongside capital.

What the Numbers Show

The source data lacks financial figures to analyze revenue or margin trends. However, the qualitative data reveals a strategic dependency on Nvidia’s software stack. Grigoryan explicitly links efficiency gains to "custom kernels" and "optimized software," indicating that hardware access alone is insufficient for their biological workloads. This suggests that Nvidia’s competitive moat in biotech lies in its full-stack optimization capabilities rather than just silicon supply.

Yorkville America CEO Steve Neamtz highlights physical constraints in the AI supply chain ahead of Nvidia Corp. (NASDAQ: NVDA) earnings. Investors will watch for signs that demand still outpaces capacity.

Neamtz argues the primary challenge is no longer capital availability but physical execution limits. He points to three specific bottlenecks emerging beyond chip production itself.

Physical Constraints on AI Buildout

The most immediate constraint involves memory, storage, and power infrastructure. Neamtz notes that compute scaling has outpaced these supporting layers. This dynamic is already impacting pricing, with reports indicating AI server prices may rise more than 15% due to soaring memory costs.

Critical minerals represent a second bottleneck. Estimates cited by Sprott suggest AI data centers could require the equivalent of about 3% of today's global rare-earth demand by 2030.

Labor shortages form the third constraint. The Associated Builders and Contractors estimates the construction industry needs 349,000 additional U.S. workers in 2026. This figure covers the entire industry rather than data centers alone.

Market Expectations and Data Center Growth

Wall Street expects Nvidia to report revenue of about $92.2 billion, nearly double last year's figure. Reuters describes the results as a test of the AI spending boom's sustainability.

Prediction market traders anticipate continued expansion in physical infrastructure. Kalshi traders assign a 66% chance the U.S. ends 2026 with at least 5,300 data centers. This compares with 4,313 U.S. data centers as of June 1, 2026.

What the Numbers Show

The divergence between massive capital expenditure and physical constraints suggests a shift in investment logic. With Big Tech set to spend more than $700 billion on capex this year, the focus moves from funding availability to execution efficiency. Neamtz indicates that if supply begins catching up with demand, the opportunity shifts from infrastructure scarcity to operational efficiency.